Corcept Therapeutics Incorporated provided revenue guidance for the fiscal 2022. For the year, the company expects revenue guidance in the range of $400 million - $430 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.52 USD | -1.15% | -2.03% | -15.27% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.27% | 2.87B | |
+38.51% | 727B | |
+33.05% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.09% | 205B | |
-5.77% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- CORT Stock
- News Corcept Therapeutics Incorporated
- Corcept Therapeutics Incorporated Provides Revenue Guidance for the Fiscal 2022